CoChat

PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

Open access

The DOI matches its Crossref record; 84 of the 87 references it cites were found in a registry or an index.

Abstract

Targeted therapy with small molecules directed at essential survival pathways in leukemia represents a major advance, including the phosphatidylinositol-3'-kinase (PI3K) p110δ inhibitor idelalisib. Here, we found that genetic inactivation of p110δ (p110δD910A/D910A) in the Eμ-TCL1 murine chronic lymphocytic leukemia (CLL) model impaired B cell receptor signaling and B cell migration, and significantly delayed leukemia pathogenesis. Regardless of TCL1 expression, p110δ inactivation led to rectal prolapse in mice resembling autoimmune colitis in patients receiving idelalisib. Moreover, we showed that p110δ inactivation in the microenvironment protected against CLL and acute myeloid leukemia. After receiving higher numbers of TCL1 leukemia cells, half of p110δD910A/D910A mice spontaneously recovered from high disease burden and resisted leukemia rechallenge. Despite disease resistance, p110δD910A/D910A mice exhibited compromised CD4+ and CD8+ T cell response, and depletion of CD4+ or CD8+ T cells restored leukemia. Interestingly, p110δD910A/D910A mice showed significantly impaired Treg expansion that associated with disease clearance. Reconstitution of p110δD910A/D910A mice with p110δWT/WT Tregs reversed leukemia resistance. Our findings suggest that p110δ inhibitors may have direct antileukemic and indirect immune-activating effects, further supporting that p110δ blockade may have a broader immune-modulatory role in types of leukemia that are not sensitive to p110δ inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci99386

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 84 references

Cited by

See all 53

Metadata

Authors
Dong, S., Harrington, B. K., Hu, E. Y., Greene, J. T., Lehman, A. M., Tran, M., Wasmuth, R. L., Long, M., Muthusamy, N., Brown, J. R., Johnson, A. J., & Byrd, J. C.
Affiliations
  • The Ohio State University (US)
  • Dana-Farber Cancer Institute (US)
Corresponding author
  • Johnson, Amy J.
  • Byrd, John C.
Venue
Journal of Clinical Investigation
Published
2018-11-19
Volume
129
Issue
1
Pages
122-136
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2900480369
Cited by
52
References
87
Citations by year
2025: 4 · 2024: 5 · 2023: 10 · 2022: 6 · 2021: 6 · 2020: 15 · 2019: 6
FWCI
3.82
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (R01CA159296)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords
PI3K p110δ, chronic lymphocytic leukemia, idelalisib, T cell suppression, regulatory T cells, B cell receptor signaling, B cell migration, acute myeloid leukemia, rectal prolapse, autoimmune colitis, tumor microenvironment, TCL1, leukemia resistance, immunomodulation
MeSH terms
Animals, Enzyme Activation, Immune Tolerance, Leukemia, Lymphoid, Mice, Transgenic, Neoplasms, Experimental, CD8-Positive T-Lymphocytes, Amino Acid Substitution, Mutation, Missense, T-Lymphocytes, Regulatory, Mice, Class I Phosphatidylinositol 3-Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. https://app.cochat.ai/papers/10.1172/jci99386
The paper
Dong, S., Harrington, B. K., Hu, E. Y., Greene, J. T., Lehman, A. M., Tran, M., Wasmuth, R. L., Long, M., Muthusamy, N., Brown, J. R., Johnson, A. J., & Byrd, J. C. (2018). PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. Journal of Clinical Investigation. https://doi.org/10.1172/jci99386

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.